Comprehensive Summary: Hepatorenal Syndrome–AKI (HRS-AKI)
Lecturer: Dr. Sanjaya Satapathy, MD, FAASLD
1. Main Clinical Topics Discussed
- Definition, classification, and updated terminology of Hepatorenal Syndrome–AKI (HRS-AKI)
- Diagnostic criteria and differentiation from AKI mimickers (ATN, pre-renal azotemia, septic shock)
- Staging of AKI in cirrhosis
- Pharmacological and supportive management strategies
- Transplant implications and timing
2. Key Learning Points, Guidelines, and Recommendations
Updated Terminology
- Type 1 HRS → now termed HRS-AKI (acute, dynamic creatinine-based definition)
- Type 2 HRS → now termed HRS-Non-AKI (HRS-NAKI) (chronic, gradual decline; associated with refractory ascites)
- Boards and clinical practice should use current nomenclature exclusively
AKI Definition in Cirrhosis
- AKI is defined by dynamic changes, not absolute thresholds:
- Rise in serum creatinine ≥0.3 mg/dL within 48 hours, OR
- ≥50% increase from baseline within 7 days
- Even small creatinine elevations are clinically significant in cirrhosis (baseline often underestimates true GFR)
AKI Staging
| Stage | Creatinine Criteria |
|---|
| 1A | <1.5 mg/dL above baseline |
| 1B | ≥1.5 mg/dL (worse prognosis than 1A) |
| 2 | 2–3× baseline increase |
| 3 | >3× baseline, or ≥4 mg/dL, or need for RRT |
Diagnostic Criteria for HRS-AKI (All Must Be Met)
- Cirrhosis with ascites meeting AKI criteria
- No improvement after diuretic withdrawal and albumin challenge (1 g/kg/day, max 100 g/day × 2 days)
- Absence of shock (septic, hypovolemic, or vasopressor-dependent)
- No nephrotoxic drug exposure (NSAIDs, aminoglycosides, contrast)
- No structural kidney disease (no significant proteinuria, hematuria/casts, normal renal ultrasound)
- HRS-AKI is a diagnosis of exclusion
Treatment Algorithm
1. Immediate steps: Discontinue diuretics and all nephrotoxins (NSAIDs, ACE inhibitors)
2. Treat precipitating infection aggressively
3. Albumin volume expansion (diagnostic and therapeutic)
4. Vasoconstrictors + albumin (cornerstone of confirmed HRS-AKI treatment):
- First-line: Terlipressin + albumin (preferred when available)
- Alternative: Norepinephrine + albumin (ICU setting)
- Least effective: Midodrine + octreotide (reserved for outpatient/oral-only settings)
Albumin Dosing
- Diagnostic phase: 1 g/kg/day (max 100 g) × 2 days
- Treatment phase: Fixed dosing of 20–40 g/day combined with vasoconstrictors
Treatment Response and Discontinuation
- Response: ≥25–30% fall in serum creatinine over 3–4 days → continue dose
- Reversal: Creatinine <1.5 mg/dL
- Stop therapy if: HRS reverses, no response after maximal trial, or ischemic complications develop (cardiac, bowel, peripheral ischemia)
- Rule of three Ss: Stop for success, stop for failure, stop for toxicity
3. Specific Clinical Data, Statistics, and Study Results Cited
- Survival curves: HRS-AKI (formerly Type 1) shows the steepest survival decline, often measured in **